Numinus Wellness Inc · OTC:NUMIF
Numinus Wellness — Q1 2024 Earnings Presentation
14 slides from Numinus Wellness's earnings presentation, January 2024
Slide 1: At the forefront of the behavioral health revolution
At the forefront of the behavioral health revolution Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF) Investor Presentation January 2024
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes certain “forward-looking information” and “forward-looking statements” (collectively “forward- looking statements”) within the meaning of applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs,
Slide 3: In Addressing the Global Mental Health Epidemic
3 In Addressing the Global Mental Health Epidemic… $1 • One in four Canadians aged 18+ screened positive for symptoms of depression, anxiety or PTSD in spring 2021, up from one in five in fall 20202 trillion • During the pandemic, ~4 in 10 adults in the U.S. reported symptoms of anxiety or depressiv
Slide 4: Psychedelic Medicines Are Having a Significant Impact
4 Psychedelic Medicines Phase 3 Results. MDMA-Assisted Therapy Are Having a Significant Impact 12% • MDMA for PTSD shows substantial clinical impact and potential annual savings of millions of dollars1 21% 67% • 2 Phase 3 trials indicated a significant improvement of PTSD of participants in the MAPS
Slide 5: Numinus: Shaping a New Path to Wellness
5 Numinus: Shaping a New Path to Wellness Global Mental Health Market1 • Unique integrated business model combines clinical therapy, US$ billion $538 psychedelic research and practitioner training • Well-positioned to benefit from the growth in psychedelic-assisted therapy across multiple indication
Slide 6: Three Complementary Businesses
6 Three Complementary Businesses Numinus Numinus Drugs/Protocols Wellness Practitioner Growing patient expected to be Clinics Training demand for treatment approved by for unaddressed regulators conditions Cedar Clinical Research Only mental healthcare company in the psychedelics sector catering to
Slide 7: Numinus Wellness Clinics Address Patient Needs Daily
7 Numinus Wellness Clinics Address Patient Needs Daily Patient Appointments 21,520 21,068 19,961 19,350 19,435 • 9 wellness clinics located in Canada and the U.S. 17,000 • Addressing a variety of mental health needs: • Depression, anxiety, bipolar disorder, substance use disorder, ADHD, OCD, PTSD, e
Slide 8: The Preferred Partner for Psychedelic Drug Development
8 The Preferred Partner for Psychedelic Drug Development Research Clients & Sponsors • Cedar Clinical Research (CCR) provides contract research site management services specializing in psychedelic medicine • Clinical research sites servicing drug developers, non-profits and academic institutions • R
Slide 9: Numinus Training to Meet High Demand for Practitioners
9 Numinus Training to Meet High Demand for Practitioners • New regulatory approvals and increased patient awareness create a bottleneck in access to treatment • Modular offering and new Learning Management System designed for working professionals and new learners • Highly scalable • 700 learners en
Slide 10: Catalysts for Future Growth
10 Catalysts for Future Growth • Regulatory reform and legal access • Colorado voted to allow psychedelic-therapy healing centers • Alberta, Canada, adopted regulatory changes that oversee (and allow) psychedelic-assisted therapies • In Australia, psilocybin and MDMA are available for prescription •
Slide 11: Financial Results
11 Financial Results For the quarter ended: For the year ended: Nov. 30, 2023 Aug. 31, 2023 Aug. 31, 2023 Aug. 31, 2022 % change % change (Q1 2024) (Q4 2023) (FY 2023) (FY 2022) Numinus Clinic Network revenues 4,925,354 4,959,680 -0.7% 19,686,534 5,744,593 242.7% Numinus Clinical Research revenues 1
Slide 12: Experienced and Aligned Management
12 Experienced and Aligned Management Payton Nyquvest Michael Tan, MBA Nikhil Handa, Dr. Reid Robison, MD, MBA Dr. Paul Thielking, MD Chief Executive Officer & Founder President and Chief Operating Chief Financial Officer Chief Clinical Officer Chief Science Officer Payton has a deep understanding o
Slide 13: A Strong Platform to Support the Future of Psychedelic Therapies
13 A Strong Platform to Support the Future of Psychedelic Therapies • Uniquely positioned as a leading provider of clinical infrastructure as novel drugs and therapeutic protocols near regulatory approval • Leading treatment expertise and IP and clinic network to support the pending commercializatio
Slide 14: At the forefront of the behavioral health revolution
At the forefront of the behavioral health revolution Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF) Email: invest@numinus.com Investor website: investors.numinus.com